Skip to main content

Our purpose is

to make every

pregnancy around

the world safer.

Learn More

Our mission is to develop and make globally available the first therapy targeting a root cause of preeclampsia.

Comanche is a biopharmaceutical company developing an investigational siRNA medicine for preterm preeclampsia. We envision a world where all women and their babies have access to safe and effective therapies for treating life threatening complications of pregnancy, and those solutions must be evidence-based and affordable.

Learn About Our WorkMeet Our Team

The
Problem

Learn More

A
Breakthrough

Learn More

Our
Science

Learn More

Patient and Survivor Resources

Read our latest news

January 30, 2025

Comanche Biopharma Awarded Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway (ILAP) Steering Group for CBP-4888, an Investigational siRNA Drug Candidate for the Treatment of sFlt1-mediated Preterm Preeclampsia

Read More

January 17, 2024

Comanche Biopharma Closes Oversubscribed $75 Million Series B Financing to Advance Mission to Develop and Make Globally Available the First Treatment Targeting a Root Cause of Preeclampsia

Read More

Contact Us

50 Beharrell St, Unit B
Concord, MA 01742

Contact Us

Comanche is a biopharmaceutical company developing an investigational siRNA medicine for preterm preeclampsia. We envision a world where all women and their babies have access to safe and effective therapies for treating life threatening complications of pregnancy, and those solutions must be evidence-based and affordable.

Sign up to receive email updates

Translate 🌎 💬